Novartis $2 million gene therapy for rare disorder is world's most expensive drug Ammar Johmani

Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.

from Reuters: Top News https://reut.rs/2K4NFcv
via IFTTT